BRIEF-Bioinvent terminates BI-505 phase II study

* Says decision follows bioinvent's review and discussion

with U.S. Food & Drug Administration (FDA), who put BI-505 on

full clinical hold in November 2016

Source text for Eikon:

Further company coverage:

Read more